Serum Cytokine Concentrations, Flavonol Intake and Colorectal Adenoma Recurrence in the Polyp Prevention Trial

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 Oct 7

PMID 20924374

Citations 8

Authors

G Bobe

G Murphy

P S Albert

L B Sansbury

E Lanza

A Schatzkin

N H Colburn

A J Cross

Affiliations

Soon will be listed here.

Abstract

Background: Serum cytokine concentrations may reflect inflammatory processes occurring during the development of colorectal neoplasms. Flavonols, bioactive compounds found in plant-based foods and beverages, may inhibit colorectal neoplasms partly by attenuating inflammation.

Methods: Using logistic regression, we estimated odds ratios (ORs) and 95% confidence intervals (CIs) to investigate the association between serum concentrations of interleukin (IL) β, 2, 8, 10, 12p70, granulocyte macrophage colony stimulating factor, interferon-γ, and tumour necrosis factor-α, measured over time, flavonol intake, estimated from a flavonol database used in conjunction with a food frequency questionnaire, and adenoma recurrence in 872 participants from the intervention arm of the Polyp Prevention Trial.

Results: Decreased IL-2 concentration during the trial increased the risk of any adenoma recurrence (4th vs 1st quartile, OR=1.68, 95% CI=1.13-2.49), whereas decreased IL-1β or IL-10 reduced the risk of advanced adenoma recurrence (OR=0.37, 95% CI=0.15-0.94; OR=0.39, 95% CI=0.15-0.98, respectively). Individuals with flavonol intake above the median (29.7 mg per day) and decreased cytokine concentrations had the lowest risk of advanced adenoma recurrence.

Conclusion: Overall, no consistent associations were observed between serum cytokine profile and colorectal adenoma recurrence; however, decreased cytokine concentrations during high flavonol consumption may indicate prevention of colorectal neoplasms.

Citing Articles

Immune battle at the premalignant stage of colorectal cancer: focus on immune cell compositions, functions and cytokine products.

Cui G Am J Cancer Res. 2020; 10(5):1308-1320.

PMID: 32509381 PMC: 7269793.

miR-370-3p Alleviates Ulcerative Colitis-Related Colorectal Cancer in Mice Through Inhibiting the Inflammatory Response and Epithelial-Mesenchymal Transition.

Lin L, Wang D, Qu S, Zhao H, Lin Y Drug Des Devel Ther. 2020; 14:1127-1141.

PMID: 32214798 PMC: 7078899. DOI: 10.2147/DDDT.S238124.

Polymorphisms in genes related to inflammation and obesity and colorectal adenoma risk.

Huang B, Tsilidis K, Smith M, Hoffman-Bolton J, Visvanathan K, Platz E Mol Carcinog. 2018; 57(10):1278-1288.

PMID: 29802748 PMC: 6697114. DOI: 10.1002/mc.22842.

Pretreatment serum interleukin-1β, interleukin-6, and tumor necrosis factor-α levels predict the progression of colorectal cancer.

Chang P, Pan Y, Fan C, Tseng W, Huang J, Wu T Cancer Med. 2016; 5(3):426-33.

PMID: 26799163 PMC: 4799955. DOI: 10.1002/cam4.602.

Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma.

Henry C, Sedjo R, Rozhok A, Salstrom J, Ahnen D, Levin T BMC Cancer. 2015; 15:123.

PMID: 25884547 PMC: 4359784. DOI: 10.1186/s12885-015-1115-2.

References

Jeong J, An J, Kwon Y, Rhee J, Lee Y . Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. J Cell Biochem. 2008; 106(1):73-82. PMC: 2736626. DOI: 10.1002/jcb.21977. View

Chun O, Chung S, Claycombe K, Song W . Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults. J Nutr. 2008; 138(4):753-60. DOI: 10.1093/jn/138.4.753. View

Pellegrini P, Berghella A, Contasta I, Del Beato T, Adorno D . The study of a patient's immune system may prove to be a useful noninvasive tool for stage classification in colon cancer. Cancer Biother Radiopharm. 2006; 21(5):443-67. DOI: 10.1089/cbr.2006.21.443. View

Lee K, Kang N, Heo Y, Rogozin E, Pugliese A, Hwang M . Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res. 2008; 68(3):946-55. PMC: 2276321. DOI: 10.1158/0008-5472.CAN-07-3140. View

Contasta I, Berghella A, Pellegrini P, Adorno D . Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm. 2003; 18(4):549-57. DOI: 10.1089/108497803322287628. View

Yoon J, Baek S . Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J. 2005; 46(5):585-96. PMC: 2562783. DOI: 10.3349/ymj.2005.46.5.585. View

Nair M, Kandaswami C, Mahajan S, Chadha K, Chawda R, Nair H . The flavonoid, quercetin, differentially regulates Th-1 (IFNgamma) and Th-2 (IL4) cytokine gene expression by normal peripheral blood mononuclear cells. Biochim Biophys Acta. 2002; 1593(1):29-36. DOI: 10.1016/s0167-4889(02)00328-2. View

Miki C, Tonouchi H, Wakuda R, Hatada T, Inoue Y, Minato E . Intra-tumoral interleukin-6 down-regulation system and genetic mutations of tumor suppressor genes in colorectal carcinoma. Cancer. 2002; 94(5):1584-92. DOI: 10.1002/cncr.10324. View

Kaminska J, Nowacki M, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M . Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor. Tumour Biol. 2005; 26(4):186-94. DOI: 10.1159/000086951. View

10.

Berghella A, Pellegrini P, Del Beato T, Maccarone D, Adorno D, Casciani C . Prognostic significance of immunological evaluation in colorectal cancer. Cancer Biother Radiopharm. 1996; 11(6):355-61. DOI: 10.1089/cbr.1996.11.355. View

11.

Grande C, Firvida J, Navas V, Casal J . Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs. 2005; 17(1):1-12. DOI: 10.1097/01.cad.0000182748.47353.51. View

12.

Lian T, Wang L, Lo Y, Huang I, Wu M . Fisetin, morin and myricetin attenuate CD36 expression and oxLDL uptake in U937-derived macrophages. Biochim Biophys Acta. 2008; 1781(10):601-9. DOI: 10.1016/j.bbalip.2008.06.009. View

13.

Park H, Lee S, Son H, Park S, Kim M, Choi E . Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Arch Pharm Res. 2008; 31(10):1303-11. DOI: 10.1007/s12272-001-2110-5. View

14.

Roselli M, Guadagni F, Martini F, Spila A, Mariotti S, DAlessandro R . Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer. Oncology. 2003; 65(2):132-8. DOI: 10.1159/000072338. View

15.

Caan B, Lanza E, Schatzkin A, Coates A, Brewer B, Slattery M . Does nutritionist review of a self-administered food frequency questionnaire improve data quality?. Public Health Nutr. 2000; 2(4):565-9. DOI: 10.1017/s1368980099000750. View

16.

Luo H, Rankin G, Liu L, Daddysman M, Jiang B, Chen Y . Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer. 2009; 61(4):554-63. PMC: 2770884. DOI: 10.1080/01635580802666281. View

17.

Phromnoi K, Yodkeeree S, Anuchapreeda S, Limtrakul P . Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. Acta Pharmacol Sin. 2009; 30(8):1169-76. PMC: 4006680. DOI: 10.1038/aps.2009.107. View

18.

Mroczko B, Szmitkowski M, Wereszczynska-Siemiatkowska U, Okulczyk B, Kedra B . Pretreatment serum levels of hematopoietic cytokines in patients with colorectal adenomas and cancer. Int J Colorectal Dis. 2006; 22(1):33-8. DOI: 10.1007/s00384-006-0099-4. View

19.

Lin W, Karin M . A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117(5):1175-83. PMC: 1857251. DOI: 10.1172/JCI31537. View

20.

Apte R, Dotan S, Elkabets M, White M, Reich E, Carmi Y . The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006; 25(3):387-408. DOI: 10.1007/s10555-006-9004-4. View